On June 30 2023, IMMUNOCORE HOLDINGS ($NASDAQ:IMCR) released their earnings results for the second quarter of FY2023. Compared to the same quarter of the previous year, total revenue increased by 49.2%, amounting to GBP 47.8 million. Unfortunately, net income for the period decreased from -6.1 million in Q2 of FY2022 to -14.1 million.
On Thursday, IMMUNOCORE HOLDINGS reported its second quarter earnings for the fiscal year 2023, and the results were record-breaking. The stock opened at $64.8 and closed at $61.7, down 3.7% from its prior closing price of $64.0.
However, the company expects these costs to be offset by the increased demand for its products in the coming quarters. Overall, IMMUNOCORE HOLDINGS had an impressive quarter with record-setting earnings and revenues. The company’s success was driven by strong demand for its immunotherapy drugs and its ongoing efforts to develop new treatments. This bodes well for the company’s future performance and investors can expect more positive results in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Immunocore Holdings. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Immunocore Holdings. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Immunocore Holdings. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Immunocore Holdings are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Immunocore Holdings Intrinsic Stock Value
GoodWhale has analyzed the fundamentals of IMMUNOCORE HOLDINGS and found that its intrinsic value is around $128.3. This was calculated with our proprietary Valuation Line, which takes into account key financial metrics such as revenue, income, margins, cash flow and more. Currently, IMMUNOCORE HOLDINGS shares are trading at $61.7, indicating the stock is undervalued by 51.9%. As a result, investors may find this to be a good opportunity to buy in at a discount. More…
Risk Rating Analysis
Star Chart Analysis
It is a leader in the field of immune-oncology, creating treatments that recruit the body’s own immune system to fight diseases. The company’s competitors in the field include Coherus BioSciences Inc, Summit Therapeutics Inc, and Akari Therapeutics PLC. All of these companies are working to develop innovative treatments for a wide range of diseases.
– Coherus BioSciences Inc ($NASDAQ:CHRS)
Coherus BioSciences Inc is a leading biologic platform company focused on the development, manufacturing and commercialization of biosimilar therapeutics. The company has a market cap of 549.11M as of 2023 and a Return on Equity of 260.65%. This market cap indicates that the company is an established player in the biologics market, while its impressive return on equity shows that it is successfully generating profits from its investments.
– Summit Therapeutics Inc ($NASDAQ:SMMT)
Summit Therapeutics Inc is a biopharmaceutical company that specializes in the discovery, development and commercialization of novel medicines for the treatment of diseases caused by bacterial infections. As of 2023, the company has a market capitalization of 340.71M. The return on equity of -53.4% indicates that the company is not generating enough revenue to cover its operating costs. Despite this, Summit Therapeutics Inc has been able to develop a range of novel medicines and is working to expand its portfolio of products.
– Akari Therapeutics PLC ($NASDAQ:AKTX)
Akari Therapeutics PLC is a biopharmaceutical company focused on the development of treatments for rare and orphan diseases. The company’s current market cap is 23.59M as of 2023, which is relatively small compared to other biopharmaceutical companies. In addition, Akari Therapeutics PLC’s Return on Equity (ROE) has been -103.31%, indicating that the company has been operating at a significant loss since its inception. As a result, the company needs to focus on improving its ROE in order to become more attractive to potential investors.
Immunocore Holdings reported their second quarter of FY2023 earnings results on June 30 2023, with total revenue of GBP 47.8 million, a 49.2% increase from Q2 of FY2022.
However, net income for the period decreased from -6.1 million in Q2 of FY2022 to -14.1 million in Q2 of FY2023. This led to a drop in stock price the same day. Investors should take this into consideration when deciding whether to invest in Immunocore Holdings. It is important to pay attention to the financial performance of the company and analyze any potential risks associated with investing in the company.
Additionally, investors should also consider any other factors that may affect the performance of Immunocore Holdings.